Breast Cancer | Specialty

Chemotherapy in Advanced Breast Cancer

November 15th 2012

Management of Metastatic Breast Cancer, Part II

November 15th 2012

Improving the Management of Metastatic Breast Cancer, Part I

November 15th 2012

Dr. Debu Tripathy Previews the Phase II GRN1005 Study

November 14th 2012

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses a phase II trial that examined GRN1005 in patients with brain metastases from breast cancer.

Dr. Hope Rugo Previews the 2012 SABCS Program

November 13th 2012

Hope S. Rugo, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, previews the 2012 San Antonio Breast Cancer Symposium program.

In Breast Cancer, Targeted Agents Boost Hormonal Therapies

November 12th 2012

Novel combinations of hormonal therapies with targeted agents show promise for improved outcomes and are likely to become part of a new paradigm for managing patients.

Lapatinib Plus Trastuzumab Bests Lapatinib Monotherapy in HER2-Positive Metastatic Breast Cancer

November 7th 2012

Investigators have documented a significant 4.5-month median overall survival advantage with lapatinib combined with trastuzumab in women with heavily pretreated HER2-positive metastatic breast cancer.

Dr. Mamounas on Neoadjuvant Chemo for Breast Cancer

November 5th 2012

Terry P. Mamounas, MD, MPH, from Aultman Hospital Cancer Center, discusses the administration of neoadjuvant chemotherapy for patients with early-stage breast cancer.

Extending Adjuvant Chemotherapy Offers No Additional Benefit in Low-Risk Primary Breast Cancer

October 29th 2012

Six cycles of doxorubicin and cyclophosphamide or single-agent paclitaxel do not lead to a superior outcome versus four cycles as adjuvant chemotherapy in women with resected primary breast cancer.

Osteoclast Inhibitors May Prevent Recurrences in Early-Stage Disease

October 26th 2012

An overview of studies looking at the potential of osteoclast inhibitors in the prevention of breast cancer recurrences in the adjuvant setting.

Management of Comorbidities in Early Breast Cancer

October 25th 2012

Novel Strategies for Treatment of Early Breast Cancer, Part II

October 25th 2012

Novel Strategies for Treatment of Early Breast Cancer, Part I

October 25th 2012

Anthracyclines for Early-Stage HER2-Positive Breast Cancer

October 25th 2012

Hormonal and HER2-Targeted Therapy in Early Breast Cancer

October 25th 2012

Dr. Aithal on the HERceptin Adjuvant (HERA) Trial

October 25th 2012

Sramila Aithal, MD, from Cancer Treatment Centers of America, discusses the HERceptin Adjuvant (HERA) trial that examined adjuvant therapy with trastuzumab for women with HER2-positive early breast cancer.

Dr. Cristofanilli Discusses ALK Amplification in IBC

October 23rd 2012

Massimo Cristofanilli, MD, from Fox Chase Cancer Center, discusses the investigation of small-molecule ALK inhibitors to treat patients with inflammatory breast cancer.

Dr. Munster on Vorinostat Plus Tamoxifen for Breast Cancer

October 23rd 2012

Pamela Munster, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses results from a phase II study that examined vorinostat in combination with tamoxifen for endocrine therapy-resistant breast cancer.

Conference Offers "Deep Dive" Into Managing Clinical Issues

October 22nd 2012

A thorough examination of emerging strategies for the treatment of breast cancer, as well as the clinical data underlying new and existing options, will form the cornerstone of the 9th Annual School of Breast Oncology.

Researchers Remain in Pursuit of Angiogenesis Inhibition

October 19th 2012

Many researchers and oncologists anticipate a role for antiangiogenic strategies in future treatment paradigms; yet just what that role will be remains elusive.